The CHASING COVID Cohort has conducted two rounds of serologic testing for SARS-CoV-2 antibodies, the first from May to September, 2020 (Period 1), and the second from November 2020 to January 2021 (Period 2). In a recent pre-print, we assess the cumulative incidence and recent incidence among the 4,235 participants who provided samples in Period 1, and the 3,615 participants who provided samples in Period 2. A total of 3,339 participants provided samples at both time points. Overall cumulative incidence across all sample timeframes was 6.8%, and the incidence of recent serconversion between the two timeframes was 9.3 new infections per 100 person-years of follow-up. We identified and quantified several policy-sensitive risk factors for recent COVID infections, highlighted persistent racial/ethnic disparities in incidence, documented continued elevated risk among essential workers, and called attention to major gaps in the coverage of public health interventions aimed at testing, isolation, and contact tracing. For more information, click here.